Skip to main content

User account menu

  • Safety Data
  • Package Inserts

Main navigation

  • Women's Health Products
    • Breast Health
    • Gynecological Health
    • Sexual Health
    • Body Composition
    • Skeletal Health
  • Lab Technologies
    • Tests
    • Cytology
    • Molecular Diagnostics
    • Collection Devices
    • Screening Technologies
  • About
    • Hologic Highlights
    • Coronavirus Update
    • Investor Relations
    • Media Library
    • Events
    • Sustainability
    • Global Access Initiative
    • Philanthropy
    • Project Health Equality
    • Hologic Timeline
    • Real Women's Stories
    • Well Woman
    • Locations
  • Support
    • Safety Data Sheets
    • Package Inserts
    • Contact
    • Medical Education
    • Order Online (iStore)
    • Contact our Compliance Hotline
  • Careers
  • Women's Health Index

Second top menu

  • Women's Health Index
  • Investors
  • Careers
  • Contact us
  • Sign in

Site selector

  • Country: USA
    • Canada
    • China
    • France
    • Germany
    • Italy
    • Japan
    • Netherlands

Site selector

  • Country: USA
    • Canada
    • China
    • France
    • Germany
    • Italy
    • Japan
    • Netherlands

User account menu

  • Safety Data
  • Package Inserts

Second top menu

  • Women's Health Index
  • Investors
  • Careers
  • Contact us
  • Sign in
Home

Main navigation (Header)

  • Women's Health Products
    • Breast Health
    • Gynecological Health
    • Sexual Health
    • Body Composition
    • Skeletal Health
  • Lab Technologies
    • Tests
    • Cytology
    • Molecular Diagnostics
    • Collection Devices
    • Screening Technologies
  • About
    • Hologic Highlights
    • Coronavirus Update
    • Investor Relations
    • Media Library
    • Events
    • Sustainability
    • Global Access Initiative
    • Philanthropy
    • Project Health Equality
    • Hologic Timeline
    • Real Women's Stories
    • Well Woman
    • Locations
  • Support
    • Safety Data Sheets
    • Package Inserts
    • Contact
    • Medical Education
    • Order Online (iStore)
    • Contact our Compliance Hotline
  • Careers
  • Women's Health Index
Home
Back to Products

Panther® Fusion System

 

Add on Panther Fusion

Find Support

Flexibility, capacity and expanded menu plus the ability to run laboratory developed tests

Add on the power to run real-time PCR, TMA and RT-TMA assays on a single, fully automated platform. With the Panther Fusion® module you can consolidate testing, increase walkaway time and enhance flexibility.

    Labor savings
    • Up to 32 assay reagent kits on board, which allow assay consolidation on a single platform

    • Ready-to-use reagent cartridges reduce manual preparation and operator errors

    • Sample throughput up to 500 tests in 8 hours increases test volume in a shift without increasing staff

    • Minimal hardware/software changes allow additional testing without extensive retraining or SOP updates

    Time savings
    • Open Access™ functionality provides full automation to run laboratory developed tests with IVDs

    • Time-to-first result at 2.4 hours allows patient results to be released sooner and improves turnaround time

    • Add on additional IVD menu without disrupting existing workflow
    Cost savings
    • Run up to 5 PCR reactions from a single (360μL) patient extraction, reducing extraction time and costs

    • 60-day onboard stability of reagents and fluids minimizes reagent waste for better cost management

    • Utilize existing Panther® system LIS connection for Panther Fusion® assays, reducing LIS costs

    • In-lab upgrade increases test volumes, throughput and menu without replacing equipment or infrastructure

    Consolidate your assay menu

    The Aptima® and Panther Fusion assays help guide patient care and enable early detection. With a menu and pipeline of world-class assays you can consolidate your molecular testing today and meet your lab’s growing needs tomorrow.

    Placeholder image

    Assays that run on the Panther Fusion System

    Women's Health

    CT/NG

    Mycoplasma genitalium 

    Trichomonas vaginalis

    Bacterial vaginosis

    Candida vaginitis/
    Trichomonas vaginalis

    HSV 1 & 2

    HPV

    HPV 16 18/24

    Zika Virus*

     

    Infectious Disease

    HIV-1 Quant Dx

    HCV

    HBV

    Flu A/B/RSV

    Paraflu

    AdV/hMPV/RV

    SARS-CoV-2*

    SARS-CoV-2/Flu/A/B*

    CMV†

    EBV

    BKV

    SARS-CoV-2/Flu/A/B/RSV†

    GI Bacterial†

    GI Extended Bacterial†

    GI Viral†

    GI Parasite†

    Find Support

    All Other Requests

    * The Aptima SARS-CoV-2, Aptima Zika Virus, Aptima SARS-CoV-2/Flu and Panther Fusion SARS-CoV-2 assays have not been FDA cleared or approved: These tests have been authorized by FDA under an EUA for use by authorized laboratories; The Aptima and Panther Fusion SARS-CoV-2 assays have been authorized only for the detection of nucleic acid from SARS-CoV-2, not for any other viruses or pathogens; The Aptima Zika Virus assay has been authorized only for the detection of nucleic acid from Zika virus, not for any other viruses or pathogens; The Aptima SARS-CoV-2/Flu assay  has been authorized only for the simultaneous qualitative detection and differentiation of nucleic acid from SARS-CoV-2, influenza A virus, influenza B virus, and not for any other viruses or pathogens. The Aptima SARS-CoV-2, Panther Fusion SARS-CoV-2, and Aptima SARS-CoV-2/Flu assays are only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of in vitro diagnostic tests for detection and/or diagnosis of COVID-19 under Section 564(b)(1) of the Act, 21 U.S.C. § 360bbb-3(b)(1), unless the authorization is terminated or revoked sooner. The Aptima Zika assay is only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of in vitro diagnostic tests for detection of Zika virus and/or diagnosis of Zika virus infection under Section 564(b)(1) of the Act, 21 U.S.C. § 360bbb-3(b)(1), unless the authorization is terminated or revoked sooner.
    † In Development and not for sale

    Related Products

    Panther Fusion® Open Access™

    Panther Fusion® Open Access™

    Panther® System

    Panther® System

    Panther® Plus

    Panther® Plus

    Panther® Link

    Panther® Link

    Panther® Trax

    Panther® Trax

    Placeholder

    Panther® Scalable Solutions

    Back to Products

    Panther® Fusion System

     

    Add on Panther Fusion

    Find Support

    Flexibility, capacity and expanded menu plus the ability to run laboratory developed tests

    Add on the power to run real-time PCR, TMA and RT-TMA assays on a single, fully automated platform. With the Panther Fusion® module you can consolidate testing, increase walkaway time and enhance flexibility.

      Labor savings
      • Up to 32 assay reagent kits on board, which allow assay consolidation on a single platform

      • Ready-to-use reagent cartridges reduce manual preparation and operator errors

      • Sample throughput up to 500 tests in 8 hours increases test volume in a shift without increasing staff

      • Minimal hardware/software changes allow additional testing without extensive retraining or SOP updates

      Time savings
      • Open Access™ functionality provides full automation to run laboratory developed tests with IVDs

      • Time-to-first result at 2.4 hours allows patient results to be released sooner and improves turnaround time

      • Add on additional IVD menu without disrupting existing workflow
      Cost savings
      • Run up to 5 PCR reactions from a single (360μL) patient extraction, reducing extraction time and costs

      • 60-day onboard stability of reagents and fluids minimizes reagent waste for better cost management

      • Utilize existing Panther® system LIS connection for Panther Fusion® assays, reducing LIS costs

      • In-lab upgrade increases test volumes, throughput and menu without replacing equipment or infrastructure

      Consolidate your assay menu

      The Aptima® and Panther Fusion assays help guide patient care and enable early detection. With a menu and pipeline of world-class assays you can consolidate your molecular testing today and meet your lab’s growing needs tomorrow.

      Placeholder image

      Assay that run on the Panther Fusion System

      Women's Health

      CT/NG

      CT

      NG

      MG

      TV

      BV

      Candida/TV

      HSV 1 & 2

      HPV

      HPV 16 18/24

      Zika Virus*

       

      Infectious Disease

      HIV-1 Quant Dx

      HCV Quant Dx

      HBV Quant

      Flu A/B/RSV

      Paraflu

      AdV/hMPV/RV

      Bordetella

      MRSA

      SARS-CoV-2*

      SARS-CoV-2/Flu/A/B*

      CMV†

      EBV†

      BKV†

      SARS-CoV-2/Flu/A/B/RSV†

      GI Bacterial

      GI Extended Bacterial

      GI Viral†

      GI Parasite†

      Find Support

      All Other Requests

      * The Aptima SARS-CoV-2, Aptima Zika Virus, Aptima SARS-CoV-2/Flu and Panther Fusion SARS-CoV-2 assays have not been FDA cleared or approved: These tests have been authorized by FDA under an EUA for use by authorized laboratories; The Aptima and Panther Fusion SARS-CoV-2 assays have been authorized only for the detection of nucleic acid from SARS-CoV-2, not for any other viruses or pathogens; The Aptima Zika Virus assay has been authorized only for the detection of nucleic acid from Zika virus, not for any other viruses or pathogens; The Aptima SARS-CoV-2/Flu assay  has been authorized only for the simultaneous qualitative detection and differentiation of nucleic acid from SARS-CoV-2, influenza A virus, influenza B virus, and not for any other viruses or pathogens. The Aptima SARS-CoV-2, Panther Fusion SARS-CoV-2, and Aptima SARS-CoV-2/Flu assays are only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of in vitro diagnostic tests for detection and/or diagnosis of COVID-19 under Section 564(b)(1) of the Act, 21 U.S.C. § 360bbb-3(b)(1), unless the authorization is terminated or revoked sooner. The Aptima Zika assay is only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of in vitro diagnostic tests for detection of Zika virus and/or diagnosis of Zika virus infection under Section 564(b)(1) of the Act, 21 U.S.C. § 360bbb-3(b)(1), unless the authorization is terminated or revoked sooner.
      † In Development and not for sale

      Related Products

      Panther Fusion® Open Access™

      Panther Fusion® Open Access™

      Panther® System

      Panther® System

      Panther® Plus

      Panther® Plus

      Panther® Link

      Panther® Link

      Panther® Trax*

      Panther® Trax*

      Panther® Scalable Solutions

      Panther® Scalable Solutions

      Main navigation (Footer)

      • Women's Health Products
        • Breast Health
        • Gynecological Health
        • Sexual Health
        • Body Composition
        • Skeletal Health
      • Lab Technologies
        • Tests
        • Cytology
        • Molecular Diagnostics
        • Collection Devices
        • Screening Technologies
      • About
        • Hologic Highlights
        • Coronavirus Update
        • Investor Relations
        • Media Library
        • Events
        • Sustainability
        • Global Access Initiative
        • Philanthropy
        • Project Health Equality
        • Hologic Timeline
        • Real Women's Stories
        • Well Woman
        • Locations
      • Support
        • Safety Data Sheets
        • Package Inserts
        • Contact
        • Medical Education
        • Order Online (iStore)
        • Contact our Compliance Hotline
      • Careers
      • Women's Health Index
      Hologic footer logo

      © Copyright 2022 Hologic, Inc. All rights reserved.

      Health logo

      Footer menu

      • Privacy Policy
      • Terms & Conditions
      • Patent Info
      • AdvaMed Code of Ethics
      • International Modern Slavery Statement

      Footer social links

      • Twitter
      • Linkedin
      • Facebook
      • Glassdoor
      • Youtube
      • Instagram